To include your compound in the COVID-19 Resource Center, submit it here.

Amgen deal gives BeiGene dry powder to grow its own pipeline

Amgen deal gives BeiGene more firepower to add to its pipeline via BD and discovery

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed portfolio and R&D pipeline. The partnership could deliver BeiGene its goal of becoming a global player.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) will co-develop 20 programs from the cancer pipeline of Amgen Inc. (NASDAQ:AMGN) in China and gain commercialization rights to the U.S. company’s three marketed cancer products.

Amgen will make a $2.7 billion equity investment in BeiGene at $174.85 per ADS, a 26% premium to BeiGene’s close on NASDAQ of $138.34 Thursday, before the deal was announced. The investment gives Amgen a 20.5% stake in the Chinese company, as well as a seat on BeiGene’s board. BeiGene ended the week up $51.22 (37%) to $189.56.

The partnership with Amgen marks the second

Read the full 1450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers